TPHA Test at Ayzal Lab

TPHA Test at Ayzal Lab

The Treponema Pallidum Hemagglutination Assay (TPHA) is a highly specific, qualitative, and semi-quantitative indirect hemagglutination laboratory test used to detect specific antibodies directed against the causative agent of syphilis, Treponema pallidum. Performed at Ayzal Lab in Lahore, Pakistan, this advanced serological investigation plays a critical role in confirming active, latent, or previously treated syphilis infections. Unlike non-treponemal screening tests such as the Venereal Disease Research Laboratory (VDRL) or Rapid Plasma Reagin (RPR) tests, which detect non-specific cardiolipin-cholesterol-lecithin antibodies, the TPHA test specifically measures immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies raised directly against the surface antigens of the Treponema pallidum bacterium.

The underlying technology of the TPHA test involves utilizing preserved avian or mammalian red blood cells coated with purified Treponema pallidum antigens. When a patient’s serum or plasma containing anti-treponemal antibodies is mixed with these sensitized erythrocytes, an immunological reaction occurs, leading to agglutination (clumping) of the red blood cells. If no antibodies are present, the cells settle to the bottom of the microtiter well, forming a distinct, compact button. This diagnostic method provides exceptional specificity and sensitivity, particularly in the secondary, latent, and late tertiary stages of syphilis, making it an indispensable confirmatory tool in clinical microbiology, venereology, and public health surveillance.

The clinical importance of the TPHA test at Ayzal Lab lies in its ability to prevent the devastating long-term systemic complications of untreated syphilis. Syphilis is a progressive sexually transmitted infection (STI) that, if left undiagnosed, can advance from localized primary chancres to systemic secondary rashes, prolonged latent periods, and eventually life-threatening tertiary manifestations, including neurosyphilis, cardiovascular syphilis, and destructive gummatous lesions. Furthermore, the test is vital in prenatal care to screen expectant mothers, preventing congenital syphilis, which can lead to spontaneous abortion, stillbirth, or severe neonatal deformities. By delivering highly accurate, reproducible, and timely serological results, Ayzal Lab aids clinicians in establishing definitive diagnoses, initiating targeted antibiotic therapy with penicillin, and monitoring epidemiological trends in the community.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the highest level of diagnostic accuracy and prevent pre-analytical errors, patients undergoing the TPHA test at Ayzal Lab should observe the following preparation guidelines:

• Fasting Requirements: Routine fasting is generally not required for the TPHA test. Patients may eat and drink normally prior to sample collection. However, if the test is ordered as part of a comprehensive fasting lipid or metabolic panel, a 10 to 12-hour fast may be necessary.
• Medication Disclosure: Patients must inform the laboratory staff and their referring physician of all current medications, including antibiotics, immunosuppressants, and high-dose biotin supplements, as these can occasionally interfere with immunological assays.
• Hydration: Staying well-hydrated by drinking plenty of water before the blood draw is highly recommended, as it facilitates easier venous access and a smoother collection process.
• Identification and Paperwork: Patients should bring their original prescription, national identity card, and any previous serological test reports (such as VDRL or RPR) to assist in clinical correlation.

During the Procedure

The TPHA test is a straightforward laboratory investigation involving a standard venipuncture. The entire procedure is conducted under strict aseptic conditions by experienced phlebotomists at Ayzal Lab:

• Patient Positioning: The patient is comfortably seated in a specialized phlebotomy chair, and their arm is extended and supported on an armrest.
• Site Selection and Cleansing: The phlebotomist examines the antecubital fossa to locate a suitable, prominent vein (typically the median cubital vein). The skin over the selected site is thoroughly sanitized using an alcohol swab and allowed to air dry completely to prevent hemolysis or contamination.
• Tourniquet Application: A sterile tourniquet is applied a few inches above the elbow to restrict venous blood flow, making the vein more visible and palpable.
• Venipuncture: Using a sterile, single-use, high-quality vacuum needle and holder system, the phlebotomist gently inserts the needle into the vein. Blood is collected into a gold-top serum separator tube (SST) or a red-top plain tube.
• Post-Collection Care: Once the required volume of blood is obtained, the tourniquet is released, the needle is smoothly withdrawn, and immediate, gentle pressure is applied to the puncture site with a sterile cotton ball to promote hemostasis. A small adhesive bandage is then applied.
• Sample Processing: The collected blood sample is left to clot at room temperature, after which it is centrifuged at high speed to separate the serum from the cellular components. The clear serum is then carefully pipetted and subjected to the TPHA assay protocol.

When is a TPHA Test Performed?

Confirmation of Reactive Screening Tests

The primary clinical indication for performing a TPHA test is to confirm a positive or reactive result obtained from non-treponemal screening assays, such as the VDRL or RPR tests. Because non-treponemal tests detect antibodies against lipid antigens released from damaged host cells, they are prone to biological false-positive results caused by pregnancy, autoimmune disorders, acute viral infections, malaria, or advanced age. The TPHA test, being highly specific to treponemal surface proteins, is utilized to rule out false positives and confirm true syphilitic infection.

Investigation of Suspected Primary or Secondary Syphilis

Physicians request a TPHA test when a patient presents with clinical signs and symptoms suggestive of active syphilis. In the primary stage, this includes the presence of a painless, indurated ulcer known as a chancre at the site of inoculation (genitals, perineum, or oral cavity). In the secondary stage, symptoms may present as a non-pruritic maculopapular rash on the palms of the hands and soles of the feet, generalized lymphadenopathy, fever, malaise, and mucosal lesions. The TPHA test helps confirm the diagnosis in these clinically symptomatic individuals.

Prenatal Screening and Maternal Care

Obstetricians routinely order treponemal serology, including the TPHA test, during early pregnancy as part of comprehensive antenatal care. Untreated maternal syphilis poses an extreme risk of transplacental transmission to the developing fetus, leading to congenital syphilis, intrauterine growth restriction, premature birth, or perinatal death. Early detection through TPHA testing allows for timely maternal administration of intramuscular Benzathine Penicillin G, which is highly effective in preventing congenital transmission and ensuring a healthy pregnancy outcome.

Evaluation of Latent or Late Tertiary Syphilis

Syphilis is known as “The Great Imitator” because it can remain clinically silent for years or even decades during the latent phase. If left untreated, it can progress to tertiary syphilis, causing severe neurological, cardiovascular, or musculoskeletal damage. Clinicians order the TPHA test when evaluating patients presenting with unexplained neurological deficits, cognitive decline, aortic aneurysms, or chronic granulomatous lesions (gummas), as the test remains highly reactive in the late stages of the disease.

Screening High-Risk Populations and Blood Donors

The TPHA test is widely used to screen individuals at an increased risk of contracting sexually transmitted infections, including those with multiple sexual partners, individuals diagnosed with other STIs (such as HIV or gonorrhea), and partners of known syphilis patients. Additionally, blood transfusion services and organ donation registries utilize TPHA testing to screen donors, ensuring the safety of the blood supply and preventing transfusion-transmitted treponemal infections.

What Does a TPHA Test Detect?

The TPHA test is designed to detect and measure specific immunological markers and clinical indicators associated with exposure to Treponema pallidum. The assay specifically identifies:

• Anti-Treponema pallidum Immunoglobulin G (IgG) antibodies
• Anti-Treponema pallidum Immunoglobulin M (IgM) antibodies
• Active, untreated primary syphilis (following the initial antibody response)
• Secondary syphilis (characterized by peak antibody titers)
• Latent syphilis (both early and late phases where clinical symptoms are absent)
• Tertiary syphilis (including neurosyphilis and cardiovascular syphilis)
• Past, successfully treated syphilis infections (as treponemal antibodies typically persist for life)
• Congenital syphilis in newborns (when interpreted alongside maternal titers and IgM-specific assays)
• True positive reactions, distinguishing them from biological false-positive VDRL/RPR results
• Agglutination patterns indicating high-titer antibody concentrations
• Non-reactive patterns indicating the absence of specific treponemal antibodies

Turnaround Time and Report Access at Ayzal Lab

At Ayzal Lab, we understand that timely diagnostic results are crucial for clinical decision-making and patient peace of mind. The TPHA test is processed using standardized, automated, and quality-controlled laboratory protocols. Under normal circumstances, the turnaround time for a TPHA test report is within 24 to 48 hours of sample collection. Once the clinical pathologist verifies and signs off on the results, patients receive an automated SMS notification. Reports can be accessed securely online through the official Ayzal Lab web portal, downloaded as a PDF, or collected in person from our main diagnostic center or designated collection points.

TPHA Findings Overview

Parameter Evaluated	Normal Findings	Possible Abnormal Findings
TPHA Qualitative Result	Non-Reactive (Negative)	Reactive (Positive)
Antibody Specificity	No specific anti-treponemal antibodies detected	Specific IgG and IgM antibodies against T. pallidum present
Clinical Interpretation	No exposure or very early stage before antibody development	Active, latent, or previously treated syphilis infection
VDRL/RPR Correlation	Both screening and confirmatory tests are negative	Reactive VDRL/RPR with Reactive TPHA confirms active infection
Agglutination Pattern	No clumping; cells settle as a compact button at the bottom	Smooth mat of agglutinated red blood cells covering the well
Congenital Evaluation	Negative maternal and neonatal antibody profiles	Reactive neonatal TPHA (requires correlation with IgM and maternal history)
Post-Treatment Status	Not applicable (uninfected)	Remains Reactive (positive) even after successful antibiotic therapy

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Ayzal Lab for TPHA Test?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified pathologists, microbiologists, and technologists who ensure strict adherence to international testing standards.
• Patient-Focused Care: We prioritize patient comfort, confidentiality, and dignity throughout the entire testing process, from registration to report delivery.
• Quality Diagnostic Services: Ayzal Lab implements rigorous internal quality control and external quality assessment programs to guarantee highly accurate and reproducible results.
• Professional Reporting: Our diagnostic reports are structured, comprehensive, and easy for both clinicians and patients to interpret.
• Modern Diagnostic Approach: We utilize state-of-the-art laboratory equipment, advanced serological assays, and automated systems to minimize human error.
• Comfortable Environment: Our collection centers are designed to provide a clean, hygienic, and stress-free environment for all patients.
• Convenient Location: Easily accessible diagnostic facilities located centrally in Lahore, Pakistan, making it convenient for routine and specialized testing.
• Commitment to Accurate Diagnosis: We are dedicated to providing precise diagnostic insights that empower physicians to make informed clinical decisions and improve patient outcomes.